Research and Development Expenses Breakdown: Viking Therapeutics, Inc. vs Xencor, Inc.

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Viking Therapeutics, Inc. and Xencor, Inc. have demonstrated contrasting strategies in their R&D investments.

Viking Therapeutics, Inc.

Since 2014, Viking Therapeutics has steadily increased its R&D expenses, growing by nearly 187% from 2014 to 2023. This upward trend reflects the company's strategic focus on expanding its therapeutic pipeline, particularly in the fields of metabolic and endocrine disorders.

Xencor, Inc.

Xencor, on the other hand, has consistently outpaced Viking in R&D spending, with a 137% increase over the same period. By 2023, Xencor's R&D expenses were approximately four times higher than those of Viking, underscoring its aggressive pursuit of novel antibody and protein-based therapeutics.

These spending patterns highlight the dynamic nature of biotech innovation, where strategic investments can shape the future of healthcare.